-
It comes as no surprise that when patients do not take their blood pressure (BP) medication, a lapse in BP control is anticipated. On the other hand, when a patient presents with an elevated BP and acknowledges omitted doses, it is difficult to be sure whether the observed elevation in BP is solely due to recent omissions, an underlying worsening of BP (requiring an augmentation rather than just simple restoration of treatment), rebound BP elevation, or some combination of these elements.
-
A systematic review covering 48 years gives pregabalin (Lyrica) Level A evidence for the treatment of diabetic neuropathy. Gabapentin, sodium valproate, amitriptyline, venlafaxine, and duloxetine may be as effective but only receive a Level B recommendation based on the quality of the studies.
-
Interpret the rhythm strip shown above. Does it represent 2nd degree AV block, Mobitz Type II? Can you be sure?
-
The first orally administered factor XA inhibitor has been approved by the FDA for the prevention of deep vein thrombosis (DVT). Rivaroxaban was developed by Bayer and is marketed in this country by Janssen Pharmaceuticals as Xarelto.
-
Clinical depression is highly prevalent in the general population and in primary care settings. Although clinicians presently have a broad array of pharmacological agents for the treatment of depression, including selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, overall response rates and remission rates with these pharmacological agents remain relatively modest.
-
-
-
Scenario: Interpret the rhythm strip shown above. Does it represent 2nd degree AV Block, Mobitz Type II? Clinically â why is it important to distinguish between Mobitz I and Mobitz II 2nd degree AV block?
-
It has recently been recognized that type 2 diabetes (DM2) increases risk for osteoporotic fracture, even though it has been demonstrated that DM2 is associated with a paradoxical increase in bone mineral density (BMD) compared to age-matched control populations. With a burgeoning prevalence of DM2 in the United States, almost 20% of the at-risk population for osteoporotic fracture has DM2, hence, clarification of risk stratification for this group is highly relevant.
-
A new orally administered macrocylic antibiotic has been approved by the FDA for the treatment of Clostridium difficile infection. Fidaxomicin is a fermentation product of Dactylosporangium aurantiacum and is marketed by Optimer Pharmaceuticals, Inc., as Dificid.